Generic placeholder image

Current Pediatric Reviews

Editor-in-Chief

ISSN (Print): 1573-3963
ISSN (Online): 1875-6336

Mini-Review Article

Genitourinary Tract Tumors in Children: An Update

Author(s): Andrés Augusto González-Arboleda, Nicolás Fernandez and Herney Andrés García-Perdomo*

Volume 18, Issue 3, 2022

Published on: 24 February, 2022

Page: [166 - 178] Pages: 13

DOI: 10.2174/1573396318666220111143902

Price: $65

conference banner
Abstract

Background: Genitourinary tract tumors in children are less common than in adults. Most of these tumors have different genetic backgrounds, clinical presentation, and oncologic behavior than their adult counterpart. As a result of low prevalence in children, some of the treatment approaches and recommendations are based on treatment experience in adult patients. However, thanks to scientific and technological development, survival rates have risen considerably.

Objective: This paper presents a review of the principal features of the tumors involving the genitourinary tract in children and an update in genetic background, diagnosis, and treatment.

Methods: A narrative review was performed on published literature about genitourinary tract tumors in pediatric patients. Papers presented in English and Spanish literature were reviewed. PubMed, Science Direct, and SciELO databases were used to collect information and present this article.

Results: Kidney tumors are the most common type of genitourinary tumors in children. Among those, Wilms tumor represents the majority of cases and shows the successful work of clinical trial groups studying this tumor type. Other tumors involving the genitourinary tract in children include Rhabdomyosarcoma, Transitional cell carcinoma, Testicular, and Adrenal tumors.

Conclusion: Genitourinary tract tumors in children represent significant morbidity and economic burden, so awareness in early diagnosis represents improvement in treatment, clinical, and oncological outcomes.

Keywords: Pediatric tumor, genitourinary tract, wilms tumor, rhabdomyosarcoma, testicular tumor, adrenal tumor.

Graphical Abstract
[1]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68(1): 7-30.
[http://dx.doi.org/10.3322/caac.21442] [PMID: 29313949]
[2]
Zderic SA. Renal and adrenal tumors in children. Urol Clin North Am 2004; 31(3): 607-617, xi.
[http://dx.doi.org/10.1016/j.ucl.2004.04.014] [PMID: 15313069]
[3]
Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M. SEER cancer statistics review, 1975-2017. National Cancer Institute 2020. Available from: www.seer.cancer.gov/archiene/csr/1975_2017.
[4]
Chintagumpala M, Pappo A, Armsby C. Presentation, diagnosis, and staging of Wilms tumor. Wolters Kluwer 2019.
[5]
Treger TD, Chowdhury T, Pritchard-Jones K, Behjati S. The genetic changes of Wilms tumour. Nat Rev Nephrol 2019; 15(4): 240-51. [Internet
[http://dx.doi.org/10.1038/s41581-019-0112-0] [PMID: 30705419]
[6]
Castellino SM, Martinez-Borges AR, McLean TW. Pediatric genitourinary tumors. Curr Opin Oncol 2009; 21(3): 278-83.
[http://dx.doi.org/10.1097/CCO.0b013e328329f201] [PMID: 19295433]
[7]
Coorens THH, Treger TD, Al-Saadi R, Moore L, Tran MGB, Mitchell TJ. Embryonal precursors of Wilms tumor. Science 2019; 366(6470): 1247-51.
[http://dx.doi.org/10.1126/science.aax1323]
[8]
McAninch J, Lue T. Smith & Tanagho’s General Urology. (18th ed). McGraw-Hill Lange 2013.
[9]
Servaes SE, Hoffer FA, Smith EA, Khanna G. Imaging of Wilms tumor: An update. Pediatr Oncol Imaging 2019; 49(11): 1441-52.
[http://dx.doi.org/10.1007/s00247-019-04423-3] [PMID: 31620845]
[10]
Irtan S, Ehrlich PF, Pritchard-Jones K. Wilms tumor: “State-of-the-art” update, 2016. Semin Pediatr Surg 2016; 25(5): 250-6.
[http://dx.doi.org/10.1053/j.sempedsurg.2016.09.003] [PMID: 27955727]
[11]
Metzger ML, Dome JS. Current therapy for Wilms’ tumor. Oncologist 2005; 10(10): 815-26.
[http://dx.doi.org/10.1634/theoncologist.10-10-815] [PMID: 16314292]
[12]
Chintagumpala M, Pappo A, Armsby C. Treatment and prognosis of Wilms tumor. Wolters Kluwer 2019.
[13]
Oostveen RM, Pritchard-Jones K. Pharmacotherapeutic management of wilms tumor: An update. Paediatr Drugs 2019; 21(1): 1-13.
[http://dx.doi.org/10.1007/s40272-018-0323-z] [PMID: 30604241]
[14]
Aldrink JH, Heaton TE, Dasgupta R, et al. Update on Wilms tumor. J Pediatr Surg 2019; 54(3): 390-7.
[http://dx.doi.org/10.1016/j.jpedsurg.2018.09.005] [PMID: 30270120]
[15]
Bouty A, Blanc T, Leclair MD, et al. Minimally invasive surgery for unilateral Wilms tumors: Multicenter retrospective analysis of 50 transperitoneal laparoscopic total nephrectomies. Pediatr Blood Cancer 2020; 67(5): e28212.
[http://dx.doi.org/10.1002/pbc.28212] [PMID: 32064752]
[16]
Vanden BRN, Bierman EN, Noord MV, Rice HE, Routh JC, Routh JC. Nephron-sparing surgery for Wilms tumor: A systematic review. Urol Oncol Semin Orig Investig 2016; 34(1): 24-32.
[http://dx.doi.org/10.1016/j.urolonc.2015.07.003] [PMID: 26254695]
[17]
Millar AJW, Cox S, Davidson A. Management of bilateral Wilms tumours. Pediatr Surg Int 2017; 33(7): 737-45.
[http://dx.doi.org/10.1007/s00383-017-4091-6] [PMID: 28516188]
[18]
Dénes FT, Duarte RJ, Cristófani LM, Lopes RI. Pediatric genitourinary oncology. Front Pediatr 2013; 1: 48.
[PMID: 24400293]
[19]
Gooskens SL, Furtwängler R, Vujanic GM, Dome JS, Graf N, van den Heuvel-Eibrink MM. Clear cell sarcoma of the kidney: A review. Eur J Cancer 2012; 48(14): 2219-26.
[http://dx.doi.org/10.1016/j.ejca.2012.04.009] [PMID: 22579455]
[20]
Aldera AP, Pillay K. Pietro, Pillay K. Clear cell sarcoma of the kidney. Arch Pathol Lab Med 2020; 144(1): 119-23.
[http://dx.doi.org/10.5858/arpa.2018-0353-RS] [PMID: 30917048]
[21]
Ahmed HU, Arya M, Levitt G, et al. Part I: Primary malignant non-Wilms’ renal tumours in children. Lancet Oncol 2007; 8(8): 730-7.
[http://dx.doi.org/10.1016/S1470-2045(07)70241-3] [PMID: 17679083]
[22]
Gooskens SL, Furtwängler R, Spreafico F, et al. Treatment and outcome of patients with relapsed clear cell sarcoma of the kidney: A combined SIOP and AIEOP study. Br J Cancer 2014; 111(2): 227-33.
[http://dx.doi.org/10.1038/bjc.2014.291] [PMID: 24937667]
[23]
Gooskens SL, Houwing ME, Vujanic GM, et al. Congenital mesoblastic nephroma 50 years after its recognition: A narrative review. Pediatr Blood Cancer 2017; 64(7): 1-9.
[http://dx.doi.org/10.1002/pbc.26437] [PMID: 28124468]
[24]
Rubin BP, Chen CJ, Morgan TW, et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol 1998; 153(5): 1451-8.
[http://dx.doi.org/10.1016/S0002-9440(10)65732-X] [PMID: 9811336]
[25]
Li Y, Liu X, Duan CF, Zhuang XH, Ge W, Song XF. Imaging manifestations of congenital mesoblastic nephroma. Clin Imaging 2021; 72: 91-6.
[http://dx.doi.org/10.1016/j.clinimag.2020.10.040] [PMID: 33217676]
[26]
Pachl M, Arul GS, Jester I, Bowen C, Hobin D, Morland B. Congenital mesoblastic nephroma: A single-centre series. Ann R Coll Surg Engl 2020; 102(1): 67-70.
[http://dx.doi.org/10.1308/rcsann.2019.0111] [PMID: 31508997]
[27]
Jehangir S, Kurian JJ, Selvarajah D, Thomas RJ, Holland AJA. Recurrent and metastatic congenital mesoblastic nephroma: Where does the evidence stand? Pediatr Surg Int 2017; 33(11): 1183-8.
[http://dx.doi.org/10.1007/s00383-017-4149-5] [PMID: 28856451]
[28]
Pawel BR. SMARCB1-deficient tumors of childhood: A practical guide. Pediatr Dev Pathol 2018; 21(1): 6-28.
[http://dx.doi.org/10.1177/1093526617749671] [PMID: 29280680]
[29]
Kohashi K, Oda Y. Oncogenic roles of SMARCB1/INI1 and its deficient tumors. Cancer Sci 2017; 108(4): 547-52.
[http://dx.doi.org/10.1111/cas.13173] [PMID: 28109176]
[30]
Morgenstern DA, Gibson S, Brown T, Sebire NJ, Anderson J. Clinical and pathological features of paediatric malignant rhabdoid tumours. Pediatr Blood Cancer 2010; 54(1): 29-34.
[http://dx.doi.org/10.1002/pbc.22231] [PMID: 19653294]
[31]
Geller JI, Roth JJ, Biegel JA. Biology and treatment of rhabdoid tumor. Crit Rev Oncog 2015; 20(3-4): 199-216.
[http://dx.doi.org/10.1615/CritRevOncog.2015013566] [PMID: 26349416]
[32]
Young EE, Brown CT, Merguerian PA, Akhavan A. Pediatric and adolescent renal cell carcinoma. Urol Oncol Semin Orig Investig 2016; 34(1): 42-9.
[PMID: 26299882]
[33]
Bruder E, Passera O, Harms D, et al. Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol 2004; 28(9): 1117-32.
[http://dx.doi.org/10.1097/01.pas.0000131558.32412.40] [PMID: 15316311]
[34]
Ray S, Jones R, Pritchard-Jones K, et al. Pediatric and young adult renal cell carcinoma. Pediatr Blood Cancer 2020; 67(11): e28675.
[http://dx.doi.org/10.1002/pbc.28675] [PMID: 32869954]
[35]
Ahmed HU, Arya M, Levitt G, Duffy PG, Mushtaq I, Sebire NJ. Part II: Treatment of primary malignant non-Wilms’ renal tumours in children. Lancet Oncol 2007; 8(8): 842-8.
[http://dx.doi.org/10.1016/S1470-2045(07)70241-3] [PMID: 17679083]
[36]
Blas L, Roberti J, Petroni J, Reniero L, Cicora F. Renal medullary carcinoma: A report of the current literature. Curr Urol Rep 2019; 20(1): 4.
[http://dx.doi.org/10.1007/s11934-019-0865-9] [PMID: 30656488]
[37]
Elliott A, Bruner E. Renal medullary carcinoma. Arch Pathol Lab Med 2019; 143(12): 1556-61.
[http://dx.doi.org/10.5858/arpa.2017-0492-RS] [PMID: 30855171]
[38]
Greco F, Faiella E, Santucci D, et al. Imaging of renal medullary carcinoma. J Kidney Cancer VHL 2017; 4(1): 1-7.
[http://dx.doi.org/10.15586/jkcvhl.2017.62] [PMID: 28405543]
[39]
Mihai R. Rare adrenal tumors in children. Semin Pediatr Surg 2014; 23(2): 71-5.
[http://dx.doi.org/10.1053/j.sempedsurg.2014.03.004] [PMID: 24931351]
[40]
Lin X, Wu D, Chen C, Zheng N. Clinical characteristics of adrenal tumors in children: A retrospective review of a 15-year single-center experience. Int Urol Nephrol 2017; 49(3): 381-5.
[http://dx.doi.org/10.1007/s11255-016-1480-z] [PMID: 27988912]
[41]
Aygun N. Biological and genetic features of neuroblastoma and their clinical importance. Curr Pediatr Rev 2018; 14(2): 73-90.
[http://dx.doi.org/10.2174/1573396314666180129101627] [PMID: 29380702]
[42]
Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther 2017; 17(4): 369-86.
[http://dx.doi.org/10.1080/14737140.2017.1285230] [PMID: 28142287]
[43]
Balassy C, Navarro OM, Daneman A. Adrenal masses in children. Radiol Clin North Am 2011; 49(4): 711-727, vi.
[http://dx.doi.org/10.1016/j.rcl.2011.05.001] [PMID: 21807170]
[44]
Armstrong R, Sridhar M, Greenhalgh KL, et al. Phaeochromocytoma in children. Arch Dis Child 2008; 93(10): 899-904.
[http://dx.doi.org/10.1136/adc.2008.139121] [PMID: 18499773]
[45]
Pinto EM, Zambetti GP, Rodriguez-Galindo C. Pediatric adrenocortical tumours. Best Pract Res Endocrinol Metab 2020; 34(3): 101448.
[http://dx.doi.org/10.1016/j.beem.2020.101448] [PMID: 32636100]
[46]
Kastenberg ZJ, Scaife ER. Adrenocortical tumors in children. Semin Pediatr Surg 2020; 29(3): 150927.
[http://dx.doi.org/10.1016/j.sempedsurg.2020.150927] [PMID: 32571512]
[47]
Lalli E, Figueiredo BC. Pediatric adrenocortical tumors: What they can tell us on adrenal development and comparison with adult adrenal tumors. Front Endocrinol (Lausanne) 2015; 6(23): 23.
[http://dx.doi.org/10.3389/fendo.2015.00023] [PMID: 25741319]
[48]
Brondani VB, Fragoso MCBV. Pediatric adrenocortical tumor-Review and management update. Curr Opin Endocrinol Diabetes Obes 2020; 27(3): 177-86.
[http://dx.doi.org/10.1097/MED.0000000000000540] [PMID: 32304390]
[49]
Lopes RI, Suartz CV, Neto RP, Berjeaut RH, Mendonca B, Almeida MQ. Management of functioning pediatric adrenal tumors. J Pediatr Surg 2021; 56(4): 768-1.
[PMID: 32972741]
[50]
Traynor MD Jr, Sada A, Thompson GB, et al. Adrenalectomy for non-neuroblastic pathology in children. Pediatr Surg Int 2020; 36(2): 129-35.
[http://dx.doi.org/10.1007/s00383-019-04589-9] [PMID: 31691026]
[51]
Chu S, Singer J. Transitional cell carcinoma in the pediatric patient: A review of the literature. Urology 2016; 91: 175-9.
[http://dx.doi.org/10.1016/j.urology.2015.12.032] [PMID: 26802795]
[52]
Rezaee ME, Dunaway CM, Baker ML, Penna FJ, Chavez DR. Urothelial cell carcinoma of the bladder in pediatric patients: A systematic review and data analysis of the world literature. J Pediatr Urol 2019; 15(4): 309-14.
[http://dx.doi.org/10.1016/j.jpurol.2019.06.013] [PMID: 31326327]
[53]
Lerena J, Krauel L, García-Aparicio L, Vallasciani S, Suñol M, Rodó J. Transitional cell carcinoma of the bladder in children and adolescents: six-case series and review of the literature. J Pediatr Urol 2010; 6(5): 481-5.
[http://dx.doi.org/10.1016/j.jpurol.2009.11.006] [PMID: 20080447]
[54]
Uçar M, Demirkaya M, Aytaç VB, Balkan E, Kılıç N. Urothelial carcinoma of the bladder in pediatric patient: Four case series and review of the literature. Balkan Med J 2018; 35(3): 268-71.
[http://dx.doi.org/10.4274/balkanmedj.2017.1292] [PMID: 29148427]
[55]
Huang H, Li X, Jin J. Treatment of bladder transitional cell carcinoma in children: A single center experience from China. Arch Iran Med 2015; 18(4): 250-2.
[PMID: 25841947]
[56]
Bujons A, Caffaratti J, Garat JM, Villavicencio H. Long-term follow-up of transitional cell carcinoma of the bladder in childhood. J Pediatr Urol 2014; 10(1): 167-70.
[http://dx.doi.org/10.1016/j.jpurol.2013.08.002] [PMID: 24035638]
[57]
Walsh TJ, Grady RW, Porter MP, Lin DW, Weiss NS. Incidence of testicular germ cell cancers in U.S. children: SEER program experience 1973 to 2000. Urology 2006; 68(2): 402-5.
[http://dx.doi.org/10.1016/j.urology.2006.02.045] [PMID: 16904461]
[58]
Bujons A, Caffaratti J, Pascual M, Angerri O, Garat JM, Villavicencio H. Testicular tumours in infancy and children. Actas Urol Esp 2011; 35(2): 93-8.
[http://dx.doi.org/10.1016/j.acuro.2010.09.005] [PMID: 21256631]
[59]
Lin X, Wu D, Zheng N, Xia Q, Han Y. Gonadal germ cell tumors in children: A retrospective review of a 10-year single-center experience. Medicine (Baltimore) 2017; 96(26): e7386.
[http://dx.doi.org/10.1097/MD.0000000000007386] [PMID: 28658171]
[60]
Fonseca A, Frazier AL, Shaikh F. Germ cell tumors in adolescents and young adults. J Oncol Pract 2019; 15(8): 433-41.
[http://dx.doi.org/10.1200/JOP.19.00190] [PMID: 31404512]
[61]
Sangüesa C, Veiga D, Llavador M, Serrano A. Testicular tumours in children: An approach to diagnosis and management with pathologic correlation. Insights Imaging 2020; 11(1): 74.
[http://dx.doi.org/10.1186/s13244-020-00867-6] [PMID: 32462465]
[62]
Cornejo KM, Frazier L, Lee RS, Kozakewich HPW, Young RH. Yolk sac tumor of the testis in infants and children: A clinicopathologic analysis of 33 cases. Am J Surg Pathol 2015; 39(8): 1121-31.
[http://dx.doi.org/10.1097/PAS.0000000000000432] [PMID: 25828390]
[63]
Chang MY, Shin HJ, Kim HG, Kim MJ, Lee MJ. Prepubertal testicular teratomas and epidermoid cysts: Comparison of clinical and sonographic features. J Ultrasound Med 2015; 34(10): 1745-51.
[http://dx.doi.org/10.7863/ultra.15.14.09032] [PMID: 26324756]
[64]
Ehrlich Y, Beck SDW, Foster RS, Bihrle R, Einhorn LH. Serum tumor markers in testicular cancer. Urol Oncol Semin Orig Investig 2013; 31(1): 17-23.
[PMID: 20822927]
[65]
Murcia-Pascual FJ, Gracia-Rodríguez R, Vázquez-Rueda F, López Pereira P, Paredes Esteban RM, Paredes-Esteban RM. Tumores testiculares y paratesticulares en la edad pediátrica. Arch Esp Urol 2016; 69(10): 691-7.
[PMID: 28042790]
[66]
Grantham EC, Caldwell BT, Cost NG. Current urologic care for testicular germ cell tumors in pediatric and adolescent patients. Urol Oncol Semin Orig Investig 2016; 34(2): 65-75.
[http://dx.doi.org/10.1016/j.urolonc.2015.06.008] [PMID: 26187598]
[67]
Ye YL, Sun XZ, Zheng FF, et al. Clinical analysis of management of pediatric testicular germ cell tumors. Urology 2012; 79(4): 892-7.
[http://dx.doi.org/10.1016/j.urology.2011.07.1422] [PMID: 22305424]
[68]
Radford A, Peycelon M, Haid B, Powis M, Lakshminarayanan B. Testicular-sparing surgery in the pediatric population: multicenter review of practice with review of the literature. Curr Opin Urol 2019; 29(5): 481-6.
[http://dx.doi.org/10.1097/MOU.0000000000000652] [PMID: 31205272]
[69]
Kooij CD, Hulsker CCC, Kranendonk MEG, et al. Testis sparing surgery in pediatric testicular tumors. Cancers (Basel) 2020; 12(10): 1-15.
[http://dx.doi.org/10.3390/cancers12102867] [PMID: 33036134]
[70]
Cecchetto G, Alaggio R, Bisogno G, et al. Sex cord-stromal tumors of the testis in children. A clinicopathologic report from the Italian TREP project. J Pediatr Surg 2010; 45(9): 1868-73.
[http://dx.doi.org/10.1016/j.jpedsurg.2010.02.120] [PMID: 20850634]
[71]
Amer KM, Thomson JE, Congiusta D, et al. Epidemiology, incidence, and survival of rhabdomyosarcoma subtypes: SEER and ICES database analysis. J Orthop Res 2019; 37(10): 2226-30.
[http://dx.doi.org/10.1002/jor.24387] [PMID: 31161653]
[72]
Skapek S, Ferrari A, Gupta A, Lupo P, Butler E, Shipley J. Rhabdomyosarcoma. Nature Rev Dis Prim 2019; 5: 1-48.
[73]
Leiner J, Le Loarer F. The current landscape of rhabdomyosarcomas: An update. Virchows Arch 2020; 476(1): 97-108.
[http://dx.doi.org/10.1007/s00428-019-02676-9] [PMID: 31696361]
[74]
Shern JF, Yohe ME, Khan J. Pediatric rhabdomyosarcoma. Crit Rev Oncog 2015; 20(3-4): 227-43.
[http://dx.doi.org/10.1615/CritRevOncog.2015013800] [PMID: 26349418]
[75]
Parham DM, Barr FG. Classification of rhabdomyosarcoma and its molecular basis. Adv Anat Pathol 2013; 20(6): 387-97.
[http://dx.doi.org/10.1097/PAP.0b013e3182a92d0d] [PMID: 24113309]
[76]
Jawad N, McHugh K. The clinical and radiologic features of paediatric rhabdomyosarcoma. Pediatr Radiol 2019; 49(11): 1516-23.
[http://dx.doi.org/10.1007/s00247-019-04386-5] [PMID: 31620851]
[77]
Rhee DS, Rodeberg DA, Baertschiger RM, et al. Update on pediatric rhabdomyosarcoma: A report from the APSA cancer committee. J Pediatr Surg 2020; 55(10): 1987-95.
[http://dx.doi.org/10.1016/j.jpedsurg.2020.06.015] [PMID: 32674846]
[78]
Saltzman AF, Cost NG. Current treatment of pediatric bladder and prostate rhabdomyosarcoma. Curr Urol Rep 2018; 19(1): 11.
[http://dx.doi.org/10.1007/s11934-018-0761-8] [PMID: 29468476]
[79]
Hawkins DS, Gupta AA, Rudzinski ER. What is new in the biology and treatment of pediatric rhabdomyosarcoma? Curr Opin Pediatr 2014; 26(1): 50-6.
[http://dx.doi.org/10.1097/MOP.0000000000000041] [PMID: 24326270]
[80]
van Erp AEM, Versleijen-Jonkers YMH, van der Graaf WTA, Fleuren EDG. Targeted therapy-based combination treatment in rhabdomyosarcoma. Mol Cancer Ther 2018; 17(7): 1365-80.
[http://dx.doi.org/10.1158/1535-7163.MCT-17-1131] [PMID: 29967215]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy